Welcome to our dedicated page for The Oncology Institute news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (Nasdaq: TOI for common stock and TOIIW for redeemable warrants) regularly issues news that reflects its role in value-based community oncology care. Company press releases highlight its efforts to advance specialized, evidence-based cancer treatment in community settings, supported by a multi-state network of clinics and affiliate locations.
News coverage often focuses on operational performance and financial updates, including quarterly financial results, guidance revisions, and discussions of revenue mix across segments such as patient services, dispensary activities, and capitation arrangements. These updates provide context on how the organization’s value-based oncology model translates into reported revenue, gross profit, and non-GAAP measures such as Adjusted EBITDA and Free Cash Flow.
Readers can also expect announcements about clinical and quality milestones. The Oncology Institute has reported results from participation in federal oncology payment models, including Medicare savings and quality scores in the Enhancing Oncology Model, and has described programs like its High Value Cancer Care initiative and 24/7 symptom management support. Other news items cover the launch of disease-focused centers, such as a Lung Cancer Center of Excellence in Florida, and the expansion of pharmacy and dispensary operations.
Corporate governance and leadership developments are another recurring theme. Recent releases have detailed board changes, including director resignations and appointments, as well as promotions within the executive team in areas such as information technology and people operations. The company also issues news about partnerships, for example its collaboration with Ascertain to deploy AI-powered automation for administrative workflows.
Investors and observers who follow TOI and TOIIW can use this news stream to monitor financial guidance, operational initiatives, technology partnerships, and clinical program developments that the company chooses to highlight in its public communications.
The Oncology Institute (NASDAQ: TOI) announced an expanded partnership with McKesson Corporation focused on drug distribution and clinical technology. This multi-year agreement aims to streamline TOI’s pharmaceutical logistics and support its growth strategy. CEO Brad Hively emphasized the importance of this partnership for enhancing high-value oncology care delivery. Since 2007, TOI has been providing specialized cancer care, performing over 57,000 infusions and prescribing more than 8,000 chemotherapeutics annually.
CERRITOS, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group, announced CEO Brad Hively's participation in the 'Value-Based Care for Medicare' panel at the Cowen FutureHealth Conference on June 22 at 3:25 pm EST. Established in 2007, TOI provides specialized, evidence-based cancer care to around 1.5 million patients through over 50 clinics and 80+ employed clinicians, advancing oncology care significantly.
On June 7, 2022, The Oncology Institute (NASDAQ: TOI) announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 27, following the annual reconstitution. This milestone reflects TOI's growth since going public in November 2021. The Russell indexes, widely utilized by investment managers, encompass 4,000 of the largest US stocks, ranked by market capitalization. Brad Hively, CEO, expressed enthusiasm for educating stakeholders about TOI's innovative oncology care and strategic achievements. Russell indexes manage approximately $12 trillion in assets.
The Oncology Institute (NASDAQ: TOI) is enhancing community cancer care in Austin, Texas, with two new clinics that opened on May 31, 2022. These facilities focus on comprehensive medical oncology services, including private exam rooms, infusion spaces, and access to clinical trials. The organization emphasizes value-based oncology care, targeting better patient outcomes and reduced financial burdens. TOI aims to disrupt the $200B industry by providing innovative treatment models while committing to patient satisfaction and community support.
The Oncology Institute, Inc. (NASDAQ: TOI) announced CEO Brad Hively's participation in two upcoming investor conferences. The first is the UBS Healthcare Conference on May 24, 2022, at 10:00 AM ET in New York, followed by the Jefferies Healthcare Conference on June 8, 2022, at 4:30 PM ET, also in New York. Interested parties can access live webcasts via the Investor Relations section of their website. Founded in 2007, TOI offers specialized, value-based cancer care to approximately 1.5 million patients across over 50 clinic locations.
The Oncology Institute, Inc. (NASDAQ: TOI) reported Q1 2022 revenue of $55 million, a 14% increase year-over-year, driven by expansion into new markets and value-based partnerships. Patient Services revenue rose 18.3% to $35 million. Gross profit increased by 20.8% to $12 million, supported by improved cost management. However, SG&A expenses surged to $30 million, up from $11 million, impacting adjusted EBITDA, which stood at $(5) million. TOI maintains its 2022 revenue guidance of $270 to $310 million, reflecting a growth of 33% to 53% over 2021.
The Oncology Institute of Hope and Innovation (TOI) has acquired Women’s Cancer Care, expanding its services into California’s Central Valley. This clinic, established in 2001, is the only facility between San Francisco and Los Angeles specializing in breast and gynecologic oncology. The partnership aims to enhance medical resources and provide advanced care solutions to women in the region. TOI now employs over 80 clinicians and expands its presence with a team of more than 30 in Fresno, enhancing its commitment to value-based cancer care.
The Oncology Institute (TOI) will announce its Q1 2022 financial results on May 11, 2022, after market close, followed by a conference call at 5:00 p.m. ET. Investors can access the call by phone or via a webcast on TOI's Investor Relations website. TOI, established in 2007, focuses on value-based cancer care, serving approximately 1.6 million patients with a team of over 80 clinicians across 50 locations. For more details about the upcoming earnings report and the company's services, visit their official website.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced substantial achievements in the latest Oncology Care Model (OCM) performance period, saving Medicare nearly $9.5M since 2016 and exceeding target savings by $5.3M. The value-based oncology group showcased above-average quality performance, equating to savings of nearly $4,000 per patient episode. With over 80 employed clinicians and expanding services, TOI emphasizes better oncological outcomes while reducing costs for cancer patients across the U.S.
The Oncology Institute of Hope and Innovation (TOI) has appointed Mihir Shah as its new chief financial officer, effective immediately. With 15 years of experience in healthcare finance, Shah has previously served in CFO roles at organizations like Commonwealth Care Alliance and Apollo Medical Holdings. He will oversee critical functions such as Accounting, Finance, and Investor Relations, aiding TOI's strategic growth. Shah takes over from Scott Dalgleish, who will assist during the transition. TOI aims to enhance oncology care through its extensive services, benefiting around 1.6 million patients.